MI Bioresearch has been sold to Covance, a subsidiary of LabCorp
MI Bioresearch is a leading preclinical immuno-oncology / oncology contract research organization, offering a unique combination of complementary services. It supports preclinical research for a diverse pharmaceutical and biotechnology customer base. It offers a broad range of human cell line and syngeneic models, supported by an array of in vitro services, in vivo pharmacology, in vivo imaging and focal beam radiation. MI Bioresearch’s comprehensive, differentiated business model leverages this range of services to better interrogate the complex pharmacology associated with cancer to provide higher-quality, decision-enabling data to its customers. For more information, visit www.mibioresearch.com.
Lincoln International acted as the exclusive investment banking advisor for MI Bioresearch and its shareholders, working closely with the company’s management team and shareholders throughout the sale process. This included creating a customized process strategy, developing the positioning, managing the buyer outreach, organizing due diligence and negotiating the transaction.
Covance is a comprehensive drug development company. Covance offers laboratory testing services to the chemical / agrochemical industries and is a market leader in toxicology services, central laboratory services, discovery services and a top global provider of Phase III clinical trial management services. For more information, visit www.covance.com.
LabCorp, an S&P 500 listed company, is a leading life sciences company, providing comprehensive clinical laboratory and end-to-end drug development services. LabCorp delivers diagnostic solutions, brings innovative medicines to patients and develops technology-enabled solutions. For more information, visit www.labcorp.com.
Meet our Senior Team
View More Transactions in Healthcare
Lincoln International advised Proclinic Group, a portfolio company of Miura Partners, on the acquisition of Meditrans
Lincoln International advised Frazier Lifesciences Acquisition Corporation on merger with NewAmsterdam Pharma Holding
Lincoln International advised Pfingsten Partners on the sale of Full Spectrum Group to CBRE Group
Lincoln International advised Rarebreed, a portfolio company of Trilantic Capital Partners and Halle Capital Management, on receiving significant investment from Revelstoke Capital Partners
Lincoln International advised Corus a portfolio company of Careventures and Quadrum Capital on the refinancing and acquisition of Nordentic
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.